Trial Profile
An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Primary, Elective, Open, Abdominal Hysterectomy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary) ; Bupivacaine
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors DURECT Corporation; Takeda Pharmaceuticals International GmbH
- 04 May 2012 Company (Takeda Global Research and Development Center) added as trial sponsor as reported by ClinicalTrials.gov.
- 21 Apr 2012 Planned number of patients changed from 224 to 230 as reported by EudraCT.
- 17 Jun 2010 Status changed from active, no longer recruiting to completed.